Analysis of adrenal masses by 18F-FDG positron emission tomography scanning

S. J. Han, T. S. Kim, S. W. Jeon, S. J. Jeong, M. Yun, Yumie Rhee, E. S. Kang, B. S. Cha, Eunjig Lee, H. C. Lee, Sungkil Lim

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

This study aimed to analyse the characteristics of adrenal masses visible in the computerised tomography (CT) scans which have been also evaluated by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography ( 18F-FDG PET), and to characterise the features of 18F-FDG PET scans associated with various adrenal endocrine tumours, especially benign functional tumours. 18F-FDG PET scans of 105 patients with adrenal masses on the CT scan were analysed. Positive uptakes in the 18F-FDG PET scans were seen in 60 malignant tumours (54 metastasic lesions, six primary adrenal cancers) and seven benign tumours. The positive predictive value of 18F-FDG PET imaging to characterise an adrenal mass as a malignant tumour was 90%; the corresponding negative predictive value to rule out malignancy was also 90%. Benign adrenal tumours were smaller than that of malignant lesions (p < 0.05). The mean standardised uptake value max (SUVmax) of the metastatic lesions [8.4 ± 6.5 (μCi/g)/μCi/kg] was significantly higher than that of the benign adrenal tumours [2.4 ± 1.2 (μCi/g)/μCi/kg, p < 0.001]. Examination of only the primary adrenal lesions revealed that all adrenocortical carcinomas, two of three cases of pheochromocytomas, three of five neuroblastomas and two of four cases of primary aldosteronism showed positive 18F-FDG uptake. In conclusion, for patients presenting adrenal masses with a high probability of malignancy, 18F-FDG PET can be used to differentiate malignant from benign adrenal lesions. However, the 18F-FDG PET uptake did not show an always consistent pattern for endocrine tumours, which was probably due to the variability inherent in 18F-FDG uptake. This study suggests that 18F-FDG PET scanning can offer supporting data to localise and characterise adrenal tumours.

Original languageEnglish
Pages (from-to)802-809
Number of pages8
JournalInternational Journal of Clinical Practice
Volume61
Issue number5
DOIs
Publication statusPublished - 2007 May 1

Fingerprint

Fluorodeoxyglucose F18
Deoxyglucose
Positron-Emission Tomography
Glandular and Epithelial Neoplasms
Neoplasms
Adrenal Gland Neoplasms
Tomography
Adrenocortical Carcinoma
Hyperaldosteronism
Pheochromocytoma
Neuroblastoma

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Han, S. J. ; Kim, T. S. ; Jeon, S. W. ; Jeong, S. J. ; Yun, M. ; Rhee, Yumie ; Kang, E. S. ; Cha, B. S. ; Lee, Eunjig ; Lee, H. C. ; Lim, Sungkil. / Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. In: International Journal of Clinical Practice. 2007 ; Vol. 61, No. 5. pp. 802-809.
@article{613d16c70feb410f983c8a2244703853,
title = "Analysis of adrenal masses by 18F-FDG positron emission tomography scanning",
abstract = "This study aimed to analyse the characteristics of adrenal masses visible in the computerised tomography (CT) scans which have been also evaluated by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography ( 18F-FDG PET), and to characterise the features of 18F-FDG PET scans associated with various adrenal endocrine tumours, especially benign functional tumours. 18F-FDG PET scans of 105 patients with adrenal masses on the CT scan were analysed. Positive uptakes in the 18F-FDG PET scans were seen in 60 malignant tumours (54 metastasic lesions, six primary adrenal cancers) and seven benign tumours. The positive predictive value of 18F-FDG PET imaging to characterise an adrenal mass as a malignant tumour was 90{\%}; the corresponding negative predictive value to rule out malignancy was also 90{\%}. Benign adrenal tumours were smaller than that of malignant lesions (p < 0.05). The mean standardised uptake value max (SUVmax) of the metastatic lesions [8.4 ± 6.5 (μCi/g)/μCi/kg] was significantly higher than that of the benign adrenal tumours [2.4 ± 1.2 (μCi/g)/μCi/kg, p < 0.001]. Examination of only the primary adrenal lesions revealed that all adrenocortical carcinomas, two of three cases of pheochromocytomas, three of five neuroblastomas and two of four cases of primary aldosteronism showed positive 18F-FDG uptake. In conclusion, for patients presenting adrenal masses with a high probability of malignancy, 18F-FDG PET can be used to differentiate malignant from benign adrenal lesions. However, the 18F-FDG PET uptake did not show an always consistent pattern for endocrine tumours, which was probably due to the variability inherent in 18F-FDG uptake. This study suggests that 18F-FDG PET scanning can offer supporting data to localise and characterise adrenal tumours.",
author = "Han, {S. J.} and Kim, {T. S.} and Jeon, {S. W.} and Jeong, {S. J.} and M. Yun and Yumie Rhee and Kang, {E. S.} and Cha, {B. S.} and Eunjig Lee and Lee, {H. C.} and Sungkil Lim",
year = "2007",
month = "5",
day = "1",
doi = "10.1111/j.1742-1241.2006.01220.x",
language = "English",
volume = "61",
pages = "802--809",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "5",

}

Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. / Han, S. J.; Kim, T. S.; Jeon, S. W.; Jeong, S. J.; Yun, M.; Rhee, Yumie; Kang, E. S.; Cha, B. S.; Lee, Eunjig; Lee, H. C.; Lim, Sungkil.

In: International Journal of Clinical Practice, Vol. 61, No. 5, 01.05.2007, p. 802-809.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of adrenal masses by 18F-FDG positron emission tomography scanning

AU - Han, S. J.

AU - Kim, T. S.

AU - Jeon, S. W.

AU - Jeong, S. J.

AU - Yun, M.

AU - Rhee, Yumie

AU - Kang, E. S.

AU - Cha, B. S.

AU - Lee, Eunjig

AU - Lee, H. C.

AU - Lim, Sungkil

PY - 2007/5/1

Y1 - 2007/5/1

N2 - This study aimed to analyse the characteristics of adrenal masses visible in the computerised tomography (CT) scans which have been also evaluated by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography ( 18F-FDG PET), and to characterise the features of 18F-FDG PET scans associated with various adrenal endocrine tumours, especially benign functional tumours. 18F-FDG PET scans of 105 patients with adrenal masses on the CT scan were analysed. Positive uptakes in the 18F-FDG PET scans were seen in 60 malignant tumours (54 metastasic lesions, six primary adrenal cancers) and seven benign tumours. The positive predictive value of 18F-FDG PET imaging to characterise an adrenal mass as a malignant tumour was 90%; the corresponding negative predictive value to rule out malignancy was also 90%. Benign adrenal tumours were smaller than that of malignant lesions (p < 0.05). The mean standardised uptake value max (SUVmax) of the metastatic lesions [8.4 ± 6.5 (μCi/g)/μCi/kg] was significantly higher than that of the benign adrenal tumours [2.4 ± 1.2 (μCi/g)/μCi/kg, p < 0.001]. Examination of only the primary adrenal lesions revealed that all adrenocortical carcinomas, two of three cases of pheochromocytomas, three of five neuroblastomas and two of four cases of primary aldosteronism showed positive 18F-FDG uptake. In conclusion, for patients presenting adrenal masses with a high probability of malignancy, 18F-FDG PET can be used to differentiate malignant from benign adrenal lesions. However, the 18F-FDG PET uptake did not show an always consistent pattern for endocrine tumours, which was probably due to the variability inherent in 18F-FDG uptake. This study suggests that 18F-FDG PET scanning can offer supporting data to localise and characterise adrenal tumours.

AB - This study aimed to analyse the characteristics of adrenal masses visible in the computerised tomography (CT) scans which have been also evaluated by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography ( 18F-FDG PET), and to characterise the features of 18F-FDG PET scans associated with various adrenal endocrine tumours, especially benign functional tumours. 18F-FDG PET scans of 105 patients with adrenal masses on the CT scan were analysed. Positive uptakes in the 18F-FDG PET scans were seen in 60 malignant tumours (54 metastasic lesions, six primary adrenal cancers) and seven benign tumours. The positive predictive value of 18F-FDG PET imaging to characterise an adrenal mass as a malignant tumour was 90%; the corresponding negative predictive value to rule out malignancy was also 90%. Benign adrenal tumours were smaller than that of malignant lesions (p < 0.05). The mean standardised uptake value max (SUVmax) of the metastatic lesions [8.4 ± 6.5 (μCi/g)/μCi/kg] was significantly higher than that of the benign adrenal tumours [2.4 ± 1.2 (μCi/g)/μCi/kg, p < 0.001]. Examination of only the primary adrenal lesions revealed that all adrenocortical carcinomas, two of three cases of pheochromocytomas, three of five neuroblastomas and two of four cases of primary aldosteronism showed positive 18F-FDG uptake. In conclusion, for patients presenting adrenal masses with a high probability of malignancy, 18F-FDG PET can be used to differentiate malignant from benign adrenal lesions. However, the 18F-FDG PET uptake did not show an always consistent pattern for endocrine tumours, which was probably due to the variability inherent in 18F-FDG uptake. This study suggests that 18F-FDG PET scanning can offer supporting data to localise and characterise adrenal tumours.

UR - http://www.scopus.com/inward/record.url?scp=34247177446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247177446&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2006.01220.x

DO - 10.1111/j.1742-1241.2006.01220.x

M3 - Article

C2 - 17343665

AN - SCOPUS:34247177446

VL - 61

SP - 802

EP - 809

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 5

ER -